Healthcare Industry News: Animas Corp
News Release - March 7, 2008
Embrella Cardiovascular, Inc. Hires Carol Burns as Vice President of Product & Business DevelopmentMALVERN, Pa.--(HSMN NewsFeed)--Embrella Cardiovascular, Inc., today announced the appointment of Carol Burns to the position of Vice President of Product and Business Development. She will report directly to Jeff O’Donnell, Chairman.
Embrella’s Chairman, Jeff O’Donnell, commented, “In our initial press release, we stated that Embrella’s Board is committed to recruiting the brightest and best to ensure success. We believe that Carol is the embodiment of that commitment. We are pleased to have her on board and believe that her prior experience working within large and small start up medical device companies will help Embrella to achieve its goals.”
Most recently, Ms. Burns was Director, International Sales & Marketing at Animas Corporation, (acquired by Johnson & Johnson) where she was responsible for developing OUS marketing strategies and generating sales for insulin pump therapy products through a worldwide distribution network. Prior to that Carol served as the Managing Director, Europe at Ventrica, Inc. (acquired by Medtronic). While living in Frankfurt, Germany she had responsibility for both European clinical trial execution and European commercialization of the first automated distal coronary anastomotic device used in coronary surgery. From 1996 to 2001. Carol worked within the cardiovascular division at Guidant Corporation on two major product platforms for endovascular abdominal aortic aneurysm repair and endoscopic vessel harvesting for coronary surgery
Ms. Burns received her B.S. degree from The College of New Jersey, in Ewing, New Jersey.
Ms. Burns commented, “It is exciting to be in on the ground floor of an early stage company like Embrella Cardiovascular. Stroke is an unfortunate complication that can occur during cardiovascular procedures. This can be devastating to patients and their families. Being part of the team to develop a device that could help in reducing the incidence of stroke will be tremendously rewarding
Embrella Cardiovascular, Inc., based in Malvern, Pennsylvania, is an early stage company dedicated to developing a unique, proprietary system to enhance embolic cerebral protection, enabling practitioners to reduce the frequency of embolic strokes during cardiovascular procedures.
Source: Embrella Cardiovascular
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.